• 

Beximco Pharma Enters EU Market 
 

News & Views

Beximco Pharma Enters EU Market  

Mar 14 2013

Beximco Pharmaceuticals Limited (BPL), a fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients has started exporting products to Europe.

Initially shipments of two ophthalmic products, Latanoprost and a combination of Latanoprost and Timolol, will be exported to Germany and Austria with other EU countries to follow. These medications are used to reduce the pressure inside the eye for people with open-angle glaucoma or intraocular hypertension (increased pressure in the eye). The Company expects to launch additional new products in the EU later this year.

Managing Director of Beximco Pharma, Nazmul Hassan MP, commented:
“Beximco has established a presence in a growing number of markets around the world. The Company is increasingly focused on penetrating large and highly regulated markets such as the EU and US, where the demand for generic products continues to rise. Beximco has developed high quality pharmaceutical facilities in Bangladesh, with a competitive cost structure for manufacturing and exporting generic drugs. This is a combination that is of increasing importance as governments strive to reduce healthcare costs without compromising on quality. We look forward to launching further products in Europe, the 2nd largest pharmaceutical market in the world with sales in excess of US$265 billion1, and providing patients with safe and affordable treatment options."


Digital Edition

Lab Asia 29.6 Dec

December 2022

In This Edition Chromatography - Optimising Viral Vector Purification Strategies with Multimodal Chromatography - Key UHPLC Characteristics Required for High throughput LC-MS - New Low Volu...

View all digital editions

Events

Arab Health

Jan 30 2023 Dubai, UAE

Nano Tech 2023

Feb 01 2023 Tokyo, Japan

Medlab Middle East

Feb 06 2023 Dubai, UAE

FILTECH

Feb 14 2023 Cologne, Germany

View all events